SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
GAITHERSBURG, Md., March 01, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. Eastern time. The conference is being held from March 6-8 in Boston, MA.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived audio of the presentation will also be available on OpGen’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] OpGen Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
